Match!

Donor-Specific HLA Antibodies as Biomarkers of Transplant Rejection

Published on Mar 1, 2019in Clinics in Laboratory Medicine1.869
路 DOI :10.1016/j.cll.2018.10.007
Olga Timofeeva17
Estimated H-index: 17
(TU: Temple University)
Abstract
  • References (141)
  • Citations (1)
馃摉 Papers frequently viewed together
1 Citations
12 Authors (Marta Crespo, ..., Pascual Julio)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References141
Newest
#1David F. Pinelli (NU: Northwestern University)H-Index: 6
#2Andrea A. Zachary (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 27
Last. Anat R. Tambur (NU: Northwestern University)H-Index: 25
view all 11 authors...
Currently, the ability to predict or monitor the efficacy of HLA antibody-removal therapies is deficient. We previously reported that titration studies are a consistent and accurate means of assessing antibody strength. To test whether titration studies can also predict which patients are better candidates for desensitization, we studied 38 patients from 3 centers (29 receiving plasmapheresis/low-dose intravenous immunoglobulin [IVIg]; 9 patients receiving high-dose IVIg). For patients undergoin...
3 CitationsSource
#1Denis Viglietti (French Institute of Health and Medical Research)H-Index: 8
#2Yassine Bouatou (Geneva College)H-Index: 4
Last. Carmen Lefaucheur (French Institute of Health and Medical Research)H-Index: 20
view all 11 authors...
A major hurdle to improving clinical care in the field of kidney transplantation is the lack of biomarkers of the response to antibody-mediated rejection (ABMR) treatment. To discover these we investigated the value of complement-binding donor-specific anti-HLA antibodies (DSAs) for evaluating the response to treatment. The study encompassed a prospective cohort of 139 kidney recipients with ABMR receiving the standard of care treatment, including plasma exchange, intravenous immunoglobulin and ...
8 CitationsSource
#1Ramsey Hachem (WashU: Washington University in St. Louis)H-Index: 28
#2Malek Kamoun (UPenn: University of Pennsylvania)H-Index: 37
Last. Roger D. Yusen (WashU: Washington University in St. Louis)H-Index: 57
view all 17 authors...
5 CitationsSource
#1Marion Rabant (Sorbonne)H-Index: 2
#2Maud Racap茅 (French Institute of Health and Medical Research)H-Index: 5
Last. Jean-Paul Duong Van Huyen (French Institute of Health and Medical Research)H-Index: 2
view all 13 authors...
4 CitationsSource
#1Fabio Ius (MHH: Hannover Medical School)H-Index: 16
#2Murielle Verboom (MHH: Hannover Medical School)H-Index: 6
Last. Gregor Warnecke (MHH: Hannover Medical School)H-Index: 24
view all 19 authors...
1 CitationsSource
#1Anat R. Tambur (NU: Northwestern University)H-Index: 25
#2Patricia Campbell (U of A: University of Alberta)H-Index: 21
Last. Peter Nickerson (UM: University of Manitoba)H-Index: 45
view all 42 authors...
28 CitationsSource
#1Antoine Bouquegneau (French Institute of Health and Medical Research)H-Index: 1
#2Charlotte Loheac (French Institute of Health and Medical Research)H-Index: 1
Last. Alexandre Loupy (French Institute of Health and Medical Research)H-Index: 15
view all 28 authors...
Background Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients鈥 access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential biomarker for optimizing graft allocation and improving the rate of successful transplantations. Methods and findings To address the clinical relevance of complement-activating anti-HLA DSAs across all ...
7 CitationsSource
#1Maria Cristina Ribeiro de Castro (USP: University of S茫o Paulo)H-Index: 10
#2Erick Acerb Barbosa (USP: University of S茫o Paulo)H-Index: 1
Last. Elias David-Neto (USP: University of S茫o Paulo)H-Index: 21
view all 11 authors...
The impact of the kinetics of the anti-HLA antibodies after KTx on the occurrence of acute rejection as well as the better time-point to monitor anti-HLA Abs after transplantation is not completely defined. This prospective study followed 150 patients over 12 months after transplantation. Serum IgG anti-HLA Abs were detected by single antigen beads after typing donors and recipients for loci A, B, C, DR, and DQ. Before KTx, 89 patients did not present anti-HLA Abs and 2% developed 鈥渄e novo鈥 Abs ...
1 CitationsSource
#1O. Omrani (QMUL: Queen Mary University of London)H-Index: 1
#2M. Al-AwwamiH-Index: 1
Last. N. SelimovicH-Index: 1
view all 4 authors...
BACKGROUND: HLA-DQ donor-specific antibodies (DSA) are implicated in allograft dysfunction after renal and lung transplantation. Limited data exists on the impact of HLA-DQ antibodies on heart tran...
1 CitationsSource
#1Gabrielle Vaughn (Boston Children's Hospital)H-Index: 2
#2Neal W. Jorgensen (UW: University of Washington)H-Index: 17
Last. Mariska S. Kemna (UW: University of Washington)H-Index: 6
view all 7 authors...
3 CitationsSource
Cited By1
Newest
#1Olga TimofeevaH-Index: 17
#2Ren茅 J. Alvarez (Thomas Jefferson University)H-Index: 2
Last. Meredith A. BriscoH-Index: 13
view all 18 authors...
Abstract Antibody-mediated rejection (AMR) of cardiac allografts mediated by anti-HLA Donor Specific Antibodies (DSA) is one of the major barriers to successful transplantation for the treatment of end-stage heart failure. Therapeutic plasma exchange (TPE) is a first-line treatment for pre-transplant desensitization. However, indications for treatment regimens and treatment end-points have not been well established. In this study, we investigated how sera dilutions could guide TPE regimens for e...
Source
#1Stacey BrannH-Index: 1
#2Steven S. GeierH-Index: 2
Last. Yoshiya ToyodaH-Index: 36
view all 6 authors...
Source